Golden Biotech Signs the Definitive Licensing Agreement with BNC Korea for the Development of Antroquinonol in COVID-19

GoldenBiotech Received FDA AoR of its Pre-EUA Meeting Request for COVID-19 Trial Drug Antroquinonol

FDA Approves GoldenBiotech's IND Application of Antroquinonol for Phase II Trial on Relapsed Acute Myeloid Leukemia (AML)

GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Patients

GoldenBiotech’s Oral COVID-19 New Drug Trial of Antroquinonol Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients

GoldenBiotech signs MOU with Sanova Pharma GesmbH for cooperation and development of Antroquinonol in 23 European Countries

GoldenBiotech HOCENA Granted Compassionate Use by the TFDA for Treatment of Covid-19 Patients

Covid-19 Trial_GoldenBiotech New Drug Antroquinonol Passed 2nd DMC Review in the USA

GoldenBiotech Completes Second Interim of Patients Enrollment for Covid-19 Phase 2 Clinical Trial_v1

GoldenBiotech Presents Outstanding Results of Potential Treatment for Relapsed AML in ASCO 2021

Covid-19 Drug Dual Achievements: GoldenBiotech’s New Drug Antroquinonol (HOCENA) Receives Positive Response from DMC Review and Licenses for 4 Countries

GoldenBiotech Signed First Licensing Agreement with BNC Korea for its New Drug Antroquinonol® (HOCENA®) to Treat Covid-19 in the Designated Territories